Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06568367 | Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | PHASE3 | RECRUITING | 520 | — | — | Aug 1, 2024 | Dec 1, 2026 | Nov 25, 2025 | 40 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| Solriamfetol 150mg | EXPERIMENTAL | Up to 12 weeks |
| Solriamfetol 300mg | EXPERIMENTAL | Up to 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Up to 12 weeks |
| Name | Type | Description |
|---|---|---|
| Solriamfetol 150 mg | DRUG | Solriamfetol tablets, taken once daily |
| Solriamfetol 300 mg | DRUG | Solriamfetol tablets, taken once daily |
| Placebo | DRUG | Placebo tablets, taken once daily |
Inclusion Criteria: * Meets International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria for Shift Work Disorder (SWD) * Provides written informed consent to participate in the study before the conduct of any study procedures. * Male or female, aged 18 to 65 inclusive. Exclusio...